Hospital
Cleveland Clinic Weston Hospital Nonprofit Corporation
Cleveland Clinic Weston Hospital Nonprofit Corporation was paid $1.93M by Medicaid between Jan 2018 and Nov 2024, across 147 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 15% of everything it billed.
33Billing provider infoCLEVELAND CLINIC WESTON HOSPITAL NONPROFIT CORPORATION
WESTON, FL 33331
WESTON, FL 33331
33aNPI1083644033assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.93M
24GClaims293,316
24DCodes billed147
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#120 of 163
Median peer was paid$4.77M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,385 | $48K | |
| 2019 | 60,577 | $304K | |
| 2020 | 58,888 | $370K | |
| 2021 | 70,446 | $536K | |
| 2022 | 55,644 | $541K | |
| 2023 | 10,066 | $128K | |
| 2024incomplete | 310 | $7K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 4,045 | 2,644 | $293K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 7,715 | 5,892 | $288K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 3,567 | 2,908 | $208K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.9% | 1,998 | 1,591 | $152K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.6% | 1,983 | 1,738 | $108K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.9% | 1,044 | 815 | $76K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.9% | 1,835 | 1,472 | $76K |
| 82962 | 3.2% | 5,223 | 2,167 | $62K | |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 22,530 | 12,375 | $59K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.0% | 724 | 585 | $59K |
| 80053 | Comprehensive metabolic panel | 2.6% | 21,687 | 13,005 | $50K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 4,021 | 3,089 | $40K |
135 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 2,927 | $39K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 1,821 | $36K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.6% | 657 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 1,263 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 3,569 | $20K |
| G0378 | Hospital observation service, per hour | <1% | 3,151 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,974 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,961 | $16K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,161 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,767 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,742 | $14K |
| 84702 | <1% | 2,059 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,511 | $12K |
| 84484 | <1% | 3,884 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,790 | $11K |
| A9270 | Non-covered item or service | <1% | 3,303 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,514 | $8K |
| 71250 | <1% | 591 | $8K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 107 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,391 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 49 | $7K |
| 86850 | <1% | 1,731 | $7K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,245 | $7K |
| 81001 | <1% | 11,640 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 215 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,865 | $5K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,592 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 361 | $4K |
| 87497 | <1% | 3,867 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 103 | $4K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 119 | $3K |
| 84100 | <1% | 8,534 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,115 | $3K |
| 83735 | <1% | 9,914 | $3K | |
| 85610 | <1% | 3,506 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,274 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 479 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,633 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 606 | $3K |
| 80197 | <1% | 7,641 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 149 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 497 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 534 | $2K |
| 82570 | <1% | 7,574 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 73 | $2K |
| 83615 | <1% | 5,263 | $2K | |
| 84156 | <1% | 6,628 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,561 | $2K |
| 86900 | <1% | 1,728 | $2K | |
| 82040 | <1% | 601 | $2K | |
| 82043 | <1% | 4,383 | $2K | |
| 87077 | <1% | 1,102 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 536 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 693 | $1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 49 | $1K |
| C1769 | Guide wire | <1% | 19 | $1K |
| 82550 | <1% | 1,705 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 704 | $1K |
| 83605 | <1% | 1,009 | $1K | |
| 86901 | <1% | 1,727 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 291 | $1K |
| 77080 | <1% | 178 | $1K | |
| 87799 | <1% | 3,838 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 206 | $995.58 |
| 96376 | <1% | 1,274 | $990.06 | |
| 83880 | <1% | 1,474 | $947.25 | |
| 83690 | <1% | 3,018 | $932.43 | |
| 80061 | Lipid panel | <1% | 3,055 | $864.42 |
| 86140 | <1% | 2,064 | $775.99 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,970 | $764.77 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,976 | $763.60 |
| 87040 | <1% | 916 | $726.43 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 32 | $667.41 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,486 | $642.07 |
| 85730 | <1% | 1,412 | $611.94 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 198 | $543.14 |
| 36430 | <1% | 19 | $507.56 | |
| 97161 | <1% | 75 | $490.13 | |
| 99152 | <1% | 270 | $480.19 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 19 | $453.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 970 | $398.58 |
| 82607 | <1% | 1,022 | $339.03 | |
| 84550 | <1% | 443 | $311.76 | |
| 0240U | <1% | 89 | $278.73 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,209 | $267.34 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 141 | $241.72 |
| 76770 | <1% | 15 | $235.77 | |
| 83540 | <1% | 880 | $223.10 | |
| 87186 | <1% | 826 | $217.45 | |
| 82728 | <1% | 758 | $206.80 | |
| 83550 | <1% | 809 | $202.12 | |
| 84155 | <1% | 502 | $195.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 502 | $192.70 |
| 83970 | <1% | 465 | $185.63 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 596 | $182.40 |
| 85652 | <1% | 716 | $182.25 | |
| 82247 | <1% | 473 | $175.46 | |
| 73630 | <1% | 17 | $164.88 | |
| 84439 | <1% | 677 | $150.63 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 37 | $150.00 |
| 93296 | <1% | 17 | $136.25 | |
| 82553 | <1% | 451 | $134.94 | |
| 84075 | <1% | 339 | $80.43 | |
| 93971 | <1% | 18 | $78.89 | |
| 87070 | <1% | 42 | $76.99 | |
| 72100 | <1% | 13 | $61.85 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 37 | $56.37 |
| 82746 | <1% | 145 | $55.66 | |
| 84295 | <1% | 122 | $45.17 | |
| 82248 | <1% | 70 | $9.99 | |
| 85379 | <1% | 409 | $9.27 | |
| 81003 | <1% | 380 | $2.12 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 170 | $1.25 |
| 81025 | <1% | 15 | $0.88 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 31 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 17 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| 85027 | 0% | 19 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
| 94760 | 0% | 57 | $0.00 | |
| 80069 | 0% | 18 | $0.00 | |
| 87340 | 0% | 17 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 19 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 24 | $0.00 |
| 82947 | 0% | 68 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 38 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 16 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 48 | $0.00 |
| 84145 | 0% | 51 | $0.00 | |
| 82565 | 0% | 49 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 18 | $0.00 |
| 84460 | 0% | 57 | $0.00 | |
| 86923 | 0% | 19 | $0.00 | |
| 93970 | 0% | 17 | $0.00 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.